Scilex Holding Company
SCLX
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $46.0M
$5.42
▲ +2.56%
P/E
—
Mkt Cap
$46.0M
52-Wk Range
$2.62–$21.34
52-Week Range
$2.62 - $21.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 75.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+24.2% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SCLX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 14, 2026
Reported EPS of -$16.65 vs -$0.18 consensus (-9083.2% surprise). Revenue of $7.6M vs $16.0M expected (-52.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-9083.2%
Revenue trend · last 2Q
—
-23%
Q1 26
Q2 26
$8.6M
$7.6M
Margins · last 2Q
Gross
51.9%
Profit
-1501.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How SCLX stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.